nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP2C9—Teniposide—lymphatic system cancer	0.158	0.35	CbGbCtD
Glipizide—CYP3A4—Cytarabine—lymphatic system cancer	0.0932	0.207	CbGbCtD
Glipizide—CYP3A4—Teniposide—lymphatic system cancer	0.0918	0.203	CbGbCtD
Glipizide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0642	0.142	CbGbCtD
Glipizide—CYP3A4—Vincristine—lymphatic system cancer	0.0442	0.0979	CbGbCtD
Glipizide—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.0196	1	CbGdCrCtD
Glipizide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00243	0.00459	CcSEcCtD
Glipizide—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00241	0.00455	CcSEcCtD
Glipizide—Malaise—Fludarabine—lymphatic system cancer	0.00241	0.00455	CcSEcCtD
Glipizide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.0024	0.00453	CcSEcCtD
Glipizide—Leukopenia—Fludarabine—lymphatic system cancer	0.00239	0.00452	CcSEcCtD
Glipizide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00238	0.0045	CcSEcCtD
Glipizide—Anorexia—Teniposide—lymphatic system cancer	0.00236	0.00447	CcSEcCtD
Glipizide—Pancytopenia—Carmustine—lymphatic system cancer	0.00233	0.0044	CcSEcCtD
Glipizide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0023	0.00435	CcSEcCtD
Glipizide—Arthralgia—Fludarabine—lymphatic system cancer	0.00227	0.0043	CcSEcCtD
Glipizide—Myalgia—Fludarabine—lymphatic system cancer	0.00227	0.0043	CcSEcCtD
Glipizide—Discomfort—Fludarabine—lymphatic system cancer	0.00225	0.00424	CcSEcCtD
Glipizide—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00224	0.00423	CcSEcCtD
Glipizide—Pancytopenia—Vincristine—lymphatic system cancer	0.00222	0.0042	CcSEcCtD
Glipizide—Dyspnoea—Teniposide—lymphatic system cancer	0.00221	0.00418	CcSEcCtD
Glipizide—Confusional state—Fludarabine—lymphatic system cancer	0.0022	0.00415	CcSEcCtD
Glipizide—Dysuria—Vincristine—lymphatic system cancer	0.00219	0.00414	CcSEcCtD
Glipizide—Oedema—Fludarabine—lymphatic system cancer	0.00218	0.00412	CcSEcCtD
Glipizide—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00217	0.00409	CcSEcCtD
Glipizide—Decreased appetite—Teniposide—lymphatic system cancer	0.00216	0.00407	CcSEcCtD
Glipizide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00214	0.00404	CcSEcCtD
Glipizide—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00214	0.00404	CcSEcCtD
Glipizide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00213	0.00403	CcSEcCtD
Glipizide—Rash—Mechlorethamine—lymphatic system cancer	0.00212	0.00401	CcSEcCtD
Glipizide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00212	0.004	CcSEcCtD
Glipizide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00211	0.00398	CcSEcCtD
Glipizide—Flushing—Bleomycin—lymphatic system cancer	0.00209	0.00394	CcSEcCtD
Glipizide—Anorexia—Fludarabine—lymphatic system cancer	0.00208	0.00393	CcSEcCtD
Glipizide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00204	0.00386	CcSEcCtD
Glipizide—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00203	0.00384	CcSEcCtD
Glipizide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00203	0.00383	CcSEcCtD
Glipizide—Chills—Bleomycin—lymphatic system cancer	0.00202	0.00381	CcSEcCtD
Glipizide—Sweating—Vincristine—lymphatic system cancer	0.002	0.00378	CcSEcCtD
Glipizide—Nausea—Mechlorethamine—lymphatic system cancer	0.002	0.00378	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00199	0.00375	CcSEcCtD
Glipizide—Jaundice—Mitoxantrone—lymphatic system cancer	0.00198	0.00375	CcSEcCtD
Glipizide—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00198	0.00373	CcSEcCtD
Glipizide—Urticaria—Teniposide—lymphatic system cancer	0.00197	0.00372	CcSEcCtD
Glipizide—Abdominal pain—Teniposide—lymphatic system cancer	0.00196	0.0037	CcSEcCtD
Glipizide—Erythema—Bleomycin—lymphatic system cancer	0.00196	0.0037	CcSEcCtD
Glipizide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00196	0.0037	CcSEcCtD
Glipizide—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00195	0.00369	CcSEcCtD
Glipizide—Sweating—Mitoxantrone—lymphatic system cancer	0.00195	0.00368	CcSEcCtD
Glipizide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00194	0.00367	CcSEcCtD
Glipizide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00192	0.00363	CcSEcCtD
Glipizide—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.0019	0.00359	CcSEcCtD
Glipizide—Decreased appetite—Fludarabine—lymphatic system cancer	0.0019	0.00358	CcSEcCtD
Glipizide—Visual impairment—Carmustine—lymphatic system cancer	0.00189	0.00358	CcSEcCtD
Glipizide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00188	0.00356	CcSEcCtD
Glipizide—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00187	0.00352	CcSEcCtD
Glipizide—Constipation—Fludarabine—lymphatic system cancer	0.00186	0.00352	CcSEcCtD
Glipizide—Pain—Fludarabine—lymphatic system cancer	0.00186	0.00352	CcSEcCtD
Glipizide—Eye disorder—Carmustine—lymphatic system cancer	0.00184	0.00347	CcSEcCtD
Glipizide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00346	CcSEcCtD
Glipizide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00183	0.00345	CcSEcCtD
Glipizide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00183	0.00345	CcSEcCtD
Glipizide—Flushing—Carmustine—lymphatic system cancer	0.00182	0.00344	CcSEcCtD
Glipizide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00182	0.00343	CcSEcCtD
Glipizide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00181	0.00342	CcSEcCtD
Glipizide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0018	0.00339	CcSEcCtD
Glipizide—Asthenia—Teniposide—lymphatic system cancer	0.00178	0.00336	CcSEcCtD
Glipizide—Malaise—Bleomycin—lymphatic system cancer	0.00177	0.00334	CcSEcCtD
Glipizide—Pruritus—Teniposide—lymphatic system cancer	0.00176	0.00332	CcSEcCtD
Glipizide—Arrhythmia—Carmustine—lymphatic system cancer	0.00175	0.00331	CcSEcCtD
Glipizide—Leukopenia—Bleomycin—lymphatic system cancer	0.00175	0.00331	CcSEcCtD
Glipizide—Erythema—Carmustine—lymphatic system cancer	0.00171	0.00323	CcSEcCtD
Glipizide—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.0017	0.00321	CcSEcCtD
Glipizide—Diarrhoea—Teniposide—lymphatic system cancer	0.0017	0.00321	CcSEcCtD
Glipizide—Myalgia—Bleomycin—lymphatic system cancer	0.00167	0.00315	CcSEcCtD
Glipizide—Discomfort—Bleomycin—lymphatic system cancer	0.00165	0.00311	CcSEcCtD
Glipizide—Chills—Mitoxantrone—lymphatic system cancer	0.00164	0.00309	CcSEcCtD
Glipizide—Urine output increased—Methotrexate—lymphatic system cancer	0.00164	0.00309	CcSEcCtD
Glipizide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00163	0.00308	CcSEcCtD
Glipizide—Confusional state—Bleomycin—lymphatic system cancer	0.00161	0.00304	CcSEcCtD
Glipizide—Vision blurred—Carmustine—lymphatic system cancer	0.00161	0.00304	CcSEcCtD
Glipizide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00161	0.00303	CcSEcCtD
Glipizide—Tremor—Carmustine—lymphatic system cancer	0.0016	0.00303	CcSEcCtD
Glipizide—Oedema—Bleomycin—lymphatic system cancer	0.0016	0.00302	CcSEcCtD
Glipizide—Erythema—Mitoxantrone—lymphatic system cancer	0.00159	0.003	CcSEcCtD
Glipizide—Vomiting—Teniposide—lymphatic system cancer	0.00158	0.00298	CcSEcCtD
Glipizide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00157	0.00296	CcSEcCtD
Glipizide—Asthenia—Fludarabine—lymphatic system cancer	0.00156	0.00295	CcSEcCtD
Glipizide—Rash—Teniposide—lymphatic system cancer	0.00156	0.00295	CcSEcCtD
Glipizide—Dermatitis—Teniposide—lymphatic system cancer	0.00156	0.00295	CcSEcCtD
Glipizide—Headache—Teniposide—lymphatic system cancer	0.00155	0.00294	CcSEcCtD
Glipizide—Pruritus—Fludarabine—lymphatic system cancer	0.00154	0.00291	CcSEcCtD
Glipizide—Leukopenia—Carmustine—lymphatic system cancer	0.00153	0.00289	CcSEcCtD
Glipizide—Anorexia—Bleomycin—lymphatic system cancer	0.00152	0.00288	CcSEcCtD
Glipizide—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0015	0.00283	CcSEcCtD
Glipizide—Polyuria—Methotrexate—lymphatic system cancer	0.0015	0.00283	CcSEcCtD
Glipizide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00149	0.00282	CcSEcCtD
Glipizide—Hypertension—Carmustine—lymphatic system cancer	0.00148	0.00279	CcSEcCtD
Glipizide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00147	0.00279	CcSEcCtD
Glipizide—Nausea—Teniposide—lymphatic system cancer	0.00147	0.00278	CcSEcCtD
Glipizide—Vertigo—Vincristine—lymphatic system cancer	0.00147	0.00277	CcSEcCtD
Glipizide—Leukopenia—Vincristine—lymphatic system cancer	0.00146	0.00276	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00146	0.00275	CcSEcCtD
Glipizide—Myalgia—Carmustine—lymphatic system cancer	0.00146	0.00275	CcSEcCtD
Glipizide—Anxiety—Carmustine—lymphatic system cancer	0.00145	0.00274	CcSEcCtD
Glipizide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00144	0.00271	CcSEcCtD
Glipizide—Malaise—Mitoxantrone—lymphatic system cancer	0.00143	0.00271	CcSEcCtD
Glipizide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00143	0.00269	CcSEcCtD
Glipizide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00142	0.00269	CcSEcCtD
Glipizide—Hypertension—Vincristine—lymphatic system cancer	0.00141	0.00266	CcSEcCtD
Glipizide—Confusional state—Carmustine—lymphatic system cancer	0.00141	0.00266	CcSEcCtD
Glipizide—Oedema—Carmustine—lymphatic system cancer	0.0014	0.00264	CcSEcCtD
Glipizide—Decreased appetite—Bleomycin—lymphatic system cancer	0.00139	0.00262	CcSEcCtD
Glipizide—Myalgia—Vincristine—lymphatic system cancer	0.00139	0.00262	CcSEcCtD
Glipizide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00139	0.00262	CcSEcCtD
Glipizide—Vomiting—Fludarabine—lymphatic system cancer	0.00139	0.00262	CcSEcCtD
Glipizide—Rash—Fludarabine—lymphatic system cancer	0.00137	0.0026	CcSEcCtD
Glipizide—Dermatitis—Fludarabine—lymphatic system cancer	0.00137	0.00259	CcSEcCtD
Glipizide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00137	0.00259	CcSEcCtD
Glipizide—Pain—Bleomycin—lymphatic system cancer	0.00137	0.00258	CcSEcCtD
Glipizide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00137	0.00258	CcSEcCtD
Glipizide—Headache—Fludarabine—lymphatic system cancer	0.00137	0.00258	CcSEcCtD
Glipizide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00256	CcSEcCtD
Glipizide—Myalgia—Mitoxantrone—lymphatic system cancer	0.00135	0.00256	CcSEcCtD
Glipizide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00135	0.00255	CcSEcCtD
Glipizide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00134	0.00253	CcSEcCtD
Glipizide—Oedema—Vincristine—lymphatic system cancer	0.00133	0.00252	CcSEcCtD
Glipizide—Anorexia—Carmustine—lymphatic system cancer	0.00133	0.00251	CcSEcCtD
Glipizide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00132	0.00249	CcSEcCtD
Glipizide—Confusional state—Mitoxantrone—lymphatic system cancer	0.00131	0.00247	CcSEcCtD
Glipizide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0013	0.00246	CcSEcCtD
Glipizide—Oedema—Mitoxantrone—lymphatic system cancer	0.0013	0.00245	CcSEcCtD
Glipizide—Nausea—Fludarabine—lymphatic system cancer	0.0013	0.00245	CcSEcCtD
Glipizide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00129	0.00243	CcSEcCtD
Glipizide—Shock—Mitoxantrone—lymphatic system cancer	0.00128	0.00241	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00127	0.0024	CcSEcCtD
Glipizide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00127	0.0024	CcSEcCtD
Glipizide—Urticaria—Bleomycin—lymphatic system cancer	0.00127	0.0024	CcSEcCtD
Glipizide—Anorexia—Vincristine—lymphatic system cancer	0.00127	0.0024	CcSEcCtD
Glipizide—Insomnia—Carmustine—lymphatic system cancer	0.00126	0.00238	CcSEcCtD
Glipizide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00125	0.00237	CcSEcCtD
Glipizide—Paraesthesia—Carmustine—lymphatic system cancer	0.00125	0.00237	CcSEcCtD
Glipizide—Dyspnoea—Carmustine—lymphatic system cancer	0.00124	0.00235	CcSEcCtD
Glipizide—Somnolence—Carmustine—lymphatic system cancer	0.00124	0.00234	CcSEcCtD
Glipizide—Anorexia—Mitoxantrone—lymphatic system cancer	0.00124	0.00234	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00121	0.00229	CcSEcCtD
Glipizide—Decreased appetite—Carmustine—lymphatic system cancer	0.00121	0.00229	CcSEcCtD
Glipizide—Insomnia—Vincristine—lymphatic system cancer	0.0012	0.00228	CcSEcCtD
Glipizide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0012	0.00228	CcSEcCtD
Glipizide—Paraesthesia—Vincristine—lymphatic system cancer	0.0012	0.00226	CcSEcCtD
Glipizide—Pain—Carmustine—lymphatic system cancer	0.00119	0.00225	CcSEcCtD
Glipizide—Constipation—Carmustine—lymphatic system cancer	0.00119	0.00225	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00118	0.00223	CcSEcCtD
Glipizide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00118	0.00222	CcSEcCtD
Glipizide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00116	0.0022	CcSEcCtD
Glipizide—Decreased appetite—Vincristine—lymphatic system cancer	0.00116	0.00219	CcSEcCtD
Glipizide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00116	0.00218	CcSEcCtD
Glipizide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00115	0.00218	CcSEcCtD
Glipizide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00115	0.00217	CcSEcCtD
Glipizide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00115	0.00217	CcSEcCtD
Glipizide—Asthenia—Bleomycin—lymphatic system cancer	0.00115	0.00217	CcSEcCtD
Glipizide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00114	0.00216	CcSEcCtD
Glipizide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00114	0.00216	CcSEcCtD
Glipizide—Constipation—Vincristine—lymphatic system cancer	0.00114	0.00215	CcSEcCtD
Glipizide—Pain—Vincristine—lymphatic system cancer	0.00114	0.00215	CcSEcCtD
Glipizide—Pruritus—Bleomycin—lymphatic system cancer	0.00113	0.00214	CcSEcCtD
Glipizide—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00113	0.00213	CcSEcCtD
Glipizide—Constipation—Mitoxantrone—lymphatic system cancer	0.00111	0.0021	CcSEcCtD
Glipizide—Pain—Mitoxantrone—lymphatic system cancer	0.00111	0.0021	CcSEcCtD
Glipizide—Abdominal pain—Carmustine—lymphatic system cancer	0.0011	0.00208	CcSEcCtD
Glipizide—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00109	0.00206	CcSEcCtD
Glipizide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00109	0.00206	CcSEcCtD
Glipizide—Pancytopenia—Methotrexate—lymphatic system cancer	0.00108	0.00204	CcSEcCtD
Glipizide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00107	0.00202	CcSEcCtD
Glipizide—Dysuria—Methotrexate—lymphatic system cancer	0.00106	0.00201	CcSEcCtD
Glipizide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00106	0.002	CcSEcCtD
Glipizide—Abdominal pain—Vincristine—lymphatic system cancer	0.00105	0.00199	CcSEcCtD
Glipizide—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00104	0.00196	CcSEcCtD
Glipizide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00103	0.00195	CcSEcCtD
Glipizide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00103	0.00194	CcSEcCtD
Glipizide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00194	CcSEcCtD
Glipizide—Vomiting—Bleomycin—lymphatic system cancer	0.00102	0.00192	CcSEcCtD
Glipizide—Drowsiness—Methotrexate—lymphatic system cancer	0.00101	0.00191	CcSEcCtD
Glipizide—Rash—Bleomycin—lymphatic system cancer	0.00101	0.0019	CcSEcCtD
Glipizide—Dermatitis—Bleomycin—lymphatic system cancer	0.00101	0.0019	CcSEcCtD
Glipizide—Asthenia—Carmustine—lymphatic system cancer	0.001	0.00189	CcSEcCtD
Glipizide—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000985	0.00186	CcSEcCtD
Glipizide—Hypersensitivity—Vincristine—lymphatic system cancer	0.000981	0.00185	CcSEcCtD
Glipizide—Sweating—Methotrexate—lymphatic system cancer	0.000972	0.00184	CcSEcCtD
Glipizide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000958	0.00181	CcSEcCtD
Glipizide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000956	0.00181	CcSEcCtD
Glipizide—Asthenia—Vincristine—lymphatic system cancer	0.000956	0.00181	CcSEcCtD
Glipizide—Diarrhoea—Carmustine—lymphatic system cancer	0.000955	0.0018	CcSEcCtD
Glipizide—Nausea—Bleomycin—lymphatic system cancer	0.00095	0.00179	CcSEcCtD
Glipizide—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000946	0.00179	CcSEcCtD
Glipizide—Asthenia—Mitoxantrone—lymphatic system cancer	0.000931	0.00176	CcSEcCtD
Glipizide—Dizziness—Carmustine—lymphatic system cancer	0.000923	0.00174	CcSEcCtD
Glipizide—Diarrhoea—Vincristine—lymphatic system cancer	0.000911	0.00172	CcSEcCtD
Glipizide—Hepatitis—Methotrexate—lymphatic system cancer	0.00091	0.00172	CcSEcCtD
Glipizide—Pharyngitis—Methotrexate—lymphatic system cancer	0.000903	0.00171	CcSEcCtD
Glipizide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000888	0.00168	CcSEcCtD
Glipizide—Vomiting—Carmustine—lymphatic system cancer	0.000887	0.00168	CcSEcCtD
Glipizide—Dizziness—Vincristine—lymphatic system cancer	0.000881	0.00166	CcSEcCtD
Glipizide—Rash—Carmustine—lymphatic system cancer	0.00088	0.00166	CcSEcCtD
Glipizide—Dermatitis—Carmustine—lymphatic system cancer	0.000879	0.00166	CcSEcCtD
Glipizide—Visual impairment—Methotrexate—lymphatic system cancer	0.000877	0.00166	CcSEcCtD
Glipizide—Headache—Carmustine—lymphatic system cancer	0.000874	0.00165	CcSEcCtD
Glipizide—Eye disorder—Methotrexate—lymphatic system cancer	0.00085	0.00161	CcSEcCtD
Glipizide—Vomiting—Vincristine—lymphatic system cancer	0.000847	0.0016	CcSEcCtD
Glipizide—Rash—Vincristine—lymphatic system cancer	0.00084	0.00159	CcSEcCtD
Glipizide—Dermatitis—Vincristine—lymphatic system cancer	0.000839	0.00158	CcSEcCtD
Glipizide—Headache—Vincristine—lymphatic system cancer	0.000834	0.00158	CcSEcCtD
Glipizide—Nausea—Carmustine—lymphatic system cancer	0.000829	0.00157	CcSEcCtD
Glipizide—Vomiting—Mitoxantrone—lymphatic system cancer	0.000825	0.00156	CcSEcCtD
Glipizide—Rash—Mitoxantrone—lymphatic system cancer	0.000818	0.00155	CcSEcCtD
Glipizide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000817	0.00154	CcSEcCtD
Glipizide—Chills—Methotrexate—lymphatic system cancer	0.000816	0.00154	CcSEcCtD
Glipizide—Headache—Mitoxantrone—lymphatic system cancer	0.000813	0.00154	CcSEcCtD
Glipizide—Erythema—Methotrexate—lymphatic system cancer	0.000792	0.0015	CcSEcCtD
Glipizide—Nausea—Vincristine—lymphatic system cancer	0.000791	0.00149	CcSEcCtD
Glipizide—Nausea—Mitoxantrone—lymphatic system cancer	0.000771	0.00146	CcSEcCtD
Glipizide—Vision blurred—Methotrexate—lymphatic system cancer	0.000746	0.00141	CcSEcCtD
Glipizide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000735	0.00139	CcSEcCtD
Glipizide—Malaise—Methotrexate—lymphatic system cancer	0.000714	0.00135	CcSEcCtD
Glipizide—Vertigo—Methotrexate—lymphatic system cancer	0.000712	0.00134	CcSEcCtD
Glipizide—Leukopenia—Methotrexate—lymphatic system cancer	0.000709	0.00134	CcSEcCtD
Glipizide—Arthralgia—Methotrexate—lymphatic system cancer	0.000674	0.00127	CcSEcCtD
Glipizide—Myalgia—Methotrexate—lymphatic system cancer	0.000674	0.00127	CcSEcCtD
Glipizide—Discomfort—Methotrexate—lymphatic system cancer	0.000666	0.00126	CcSEcCtD
Glipizide—Confusional state—Methotrexate—lymphatic system cancer	0.000652	0.00123	CcSEcCtD
Glipizide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000633	0.0012	CcSEcCtD
Glipizide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000625	0.00118	CcSEcCtD
Glipizide—Anorexia—Methotrexate—lymphatic system cancer	0.000616	0.00116	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000589	0.00111	CcSEcCtD
Glipizide—Insomnia—Methotrexate—lymphatic system cancer	0.000585	0.0011	CcSEcCtD
Glipizide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00058	0.0011	CcSEcCtD
Glipizide—Dyspnoea—Methotrexate—lymphatic system cancer	0.000576	0.00109	CcSEcCtD
Glipizide—Somnolence—Methotrexate—lymphatic system cancer	0.000575	0.00109	CcSEcCtD
Glipizide—Dyspepsia—Methotrexate—lymphatic system cancer	0.000569	0.00107	CcSEcCtD
Glipizide—Decreased appetite—Methotrexate—lymphatic system cancer	0.000562	0.00106	CcSEcCtD
Glipizide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000558	0.00105	CcSEcCtD
Glipizide—Pain—Methotrexate—lymphatic system cancer	0.000553	0.00104	CcSEcCtD
Glipizide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000533	0.00101	CcSEcCtD
Glipizide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000529	0.000998	CcSEcCtD
Glipizide—Urticaria—Methotrexate—lymphatic system cancer	0.000513	0.00097	CcSEcCtD
Glipizide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000511	0.000965	CcSEcCtD
Glipizide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000476	0.000899	CcSEcCtD
Glipizide—Asthenia—Methotrexate—lymphatic system cancer	0.000464	0.000876	CcSEcCtD
Glipizide—Pruritus—Methotrexate—lymphatic system cancer	0.000457	0.000864	CcSEcCtD
Glipizide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000442	0.000835	CcSEcCtD
Glipizide—Dizziness—Methotrexate—lymphatic system cancer	0.000427	0.000807	CcSEcCtD
Glipizide—Vomiting—Methotrexate—lymphatic system cancer	0.000411	0.000776	CcSEcCtD
Glipizide—Rash—Methotrexate—lymphatic system cancer	0.000408	0.00077	CcSEcCtD
Glipizide—Dermatitis—Methotrexate—lymphatic system cancer	0.000407	0.000769	CcSEcCtD
Glipizide—Headache—Methotrexate—lymphatic system cancer	0.000405	0.000765	CcSEcCtD
Glipizide—Nausea—Methotrexate—lymphatic system cancer	0.000384	0.000725	CcSEcCtD
